Abridge revenue and valuation
Specter estimates Abridge's annual revenue at $136M to $360M and its valuation at $4.75B to $6.64B. The company last reported $117M ARR in June 2025 and was priced at $5.3B in June 2025.
- Estimated revenue
- $136M–$360M
- Estimated valuation
- $4.75B–$6.64B
- Reported ARR
- $117M
- Total funding
- $780M
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 676
Abridge revenue
Abridge last reported $117M ARR in June 2025. Specter's model puts current ARR between $136M and $360M.
Monthly data
| Month | Specter estimate | Low | High | Reported ARR |
|---|---|---|---|---|
| $220M | $136M | $360M | ||
| $195M | $127M | $300M | ||
| $198M | $134M | $290M | ||
| $193M | $129M | $290M | ||
| $186M | $126M | $270M | ||
| $160M | $99M | $260M | ||
| $153M | $96M | $240M | ||
| $150M | $97M | $230M | ||
| $147M | $95M | $230M | ||
| $146M | $98M | $220M | ||
| $137M | $91M | $200M | ||
| $135M | $96M | $190M | ||
| $132M | $96M | $182M | ||
| $129M | $94M | $176M | ||
| $129M | $99M | $167M | ||
| $124M | $99M | $155M | ||
| $117M | $97M | $141M | $117M | |
| $52M | $23M | $81M | ||
| $48M | $21M | $75M | ||
| $48M | $16M | $81M | ||
| $42M | $14M | $71M | ||
| $34M | $13M | $55M | ||
| $31M | $11M | $51M | ||
| $26M | $10M | $42M | ||
| $26M | $10M | $42M | ||
| $19M | $6.7M | $32M | ||
| $30M | $6.7M | $52M | ||
| $21M | $4.3M | $38M | ||
| $15M | $6M | $25M |
| Date | Reported ARR | Source |
|---|---|---|
| $117M |
Abridge valuation
Abridge's valuation rose from $850M at its Series C in February 2024 to $5.3B at its Series E in June 2025. Specter's live estimate sits between $4.75B and $6.64B.
Monthly data
| Month | Specter estimate | Low | High | Reported valuation |
|---|---|---|---|---|
| $5.62B | $4.75B | $6.64B | ||
| $5.1B | $3.7B | $7.03B | ||
| $5.08B | $3.85B | $6.71B | ||
| $5.07B | $3.98B | $6.44B | ||
| $5.14B | $4.18B | $6.33B | ||
| $5.3B | $4.41B | $6.37B | $5.3B (press) | |
| $5.3B | $3.92B | $7.16B | ||
| $5.3B | $4.13B | $6.8B | ||
| $5.3B | $4.2B | $6.69B | ||
| $5.3B | $4.31B | $6.52B | ||
| $5.3B | $4.37B | $6.42B | ||
| $5.3B | $4.41B | $6.37B | $5.3B (press) | |
| $5.3B | $4.31B | $6.51B | ||
| $5.3B | $4.37B | $6.42B | ||
| $5.3B | $4.41B | $6.37B | $5.3B (press) | |
| $5.3B | $4.41B | $6.37B | $5.3B (press) | |
| $5.3B | $4.41B | $6.37B | $5.3B (round) | |
| $4.5B | $3.59B | $5.64B | ||
| $3.82B | $3.11B | $4.68B | ||
| $3.24B | $2.67B | $3.93B | ||
| $2.75B | $2.29B | $3.31B | $2.75B (round) | |
| $2.99B | $2.17B | $4.11B | ||
| $3.24B | $2.39B | $4.4B | ||
| $3.52B | $2.55B | $4.85B | ||
| $3.82B | $2.85B | $5.12B | ||
| $4.14B | $3.11B | $5.52B | ||
| $4.5B | $3.52B | $5.75B | ||
| $4.88B | $3.98B | $5.99B | ||
| $5.3B | $4.41B | $6.37B | $5.3B (press) |
Abridge funding rounds
| Date | Round | Raised | Post-money valuation | Lead investors |
|---|---|---|---|---|
| Corporate round | Undisclosed | Undisclosed | Eli Lilly | |
| Venture round | $22.5M | Undisclosed | Undisclosed | |
| Series E | $300M | $5.3B | Andreessen Horowitz, Khosla Ventures | |
| Series D | $250M | $2.75B | IVP, Elad Gil | |
| Series C | $150M | $850M | Redpoint, Lightspeed Venture Partners | |
| Series B | $30M | Undisclosed | Spark Capital | |
| Corporate round | Undisclosed | Undisclosed | IKS Health | |
| Series A | $12.5M | Undisclosed | Wittington Ventures | |
| Series A | $10M | Undisclosed | Union Square Ventures, UPMC | |
| Seed | $5M | Undisclosed | Undisclosed |
Abridge competitors
The AI medical scribe market pits broad clinical automation against specialized documentation workflows.
| Company | Revenue | Valuation |
|---|---|---|
| $136M–$360M | $4.75B–$6.64B | |
| $8.3M–$53M | $950M–$1.52B | |
| $26M–$173M | $1.04B–$1.13B | |
| $11M–$87M | $68M–$440M | |
| $55M–$85M | $810M–$1.16B |
Abridge revenue and valuation FAQ
What is Abridge's revenue?
Specter estimates Abridge's annual recurring revenue at $136M to $360M as of October 2026. Abridge last reported $117M ARR in June 2025.
What is Abridge's valuation?
Abridge's latest post-money valuation is $5.3B, from a June 2025 Series E. Specter's live estimate is $4.75B to $6.64B.
What is Abridge's revenue multiple?
Abridge is valued at about 45.3× ARR, based on its $5.3B June 2025 valuation and $117M last reported ARR.
How much funding has Abridge raised?
$780M across 10 rounds, from a $5M Seed in July 2019 to a corporate round in June 2026.
Who invested in Abridge?
35 investors, including Andreessen Horowitz, Elad Gil, Eli Lilly, IVP, Khosla Ventures and Redpoint.
Who are Abridge's competitors?
Ambience Healthcare, Suki AI, Augmedix and Heidi. Specter ranks 30 competitors for Abridge.